CXCL10 and glioblastoma: Their results showed that among 129 analyzable samples, strong CXCR3 and CXCL10 expression was observed in 72.7 and 50.7% of GBM cases, respectively, whereas CXCR3 and CXCL10 expression in DA cases was 31.8 and 24.5%, respectively.